B
Bengt Hamrén
Researcher at AstraZeneca
Publications - 36
Citations - 956
Bengt Hamrén is an academic researcher from AstraZeneca. The author has contributed to research in topics: Population & Tesaglitazar. The author has an hindex of 12, co-authored 33 publications receiving 752 citations. Previous affiliations of Bengt Hamrén include Uppsala University & Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Paul Morgan,Dean G. Brown,Simon Lennard,Mark J. Anderton,J. Carl Barrett,Ulf G. Eriksson,Mark Fidock,Bengt Hamrén,Anthony Johnson,Ruth March,James Matcham,Jerome T. Mettetal,David J. Nicholls,Stefan Platz,Steve Rees,Michael A. Snowden,Menelas N. Pangalos +16 more
TL;DR: The evolution of the approach to target validation, hit and lead optimization, pharmacokinetic/pharmacodynamic modelling and drug safety testing, which have helped improve the quality of candidate drug nomination, as well as the development of the right culture.
Journal ArticleDOI
Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation
Scott Marshall,Rolf Burghaus,V Cosson,Sya Cheung,Marylore Chenel,O DellaPasqua,N Frey,Bengt Hamrén,Lutz Harnisch,F Ivanow,Thomas Kerbusch,Jörg Lippert,Peter A. Milligan,S Rohou,Alexander Staab,JL Steimer,C Tornøe,Sag Visser +17 more
TL;DR: This document was developed to enable greater consistency in the practice, application, and documentation of Model‐Informed Drug Discovery and Development (MID3) across the pharmaceutical industry.
Journal ArticleDOI
Models for Plasma Glucose, HbA1c, and Hemoglobin Interrelationships in Patients with Type 2 Diabetes Following Tesaglitazar Treatment
TL;DR: The model indicated that the tesaglitazar effect on Hb was caused by hemodilution of RBCs, and a mechanism‐based PD model for the FPG–HbA1c relationship was developed.
Journal ArticleDOI
Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development
TL;DR: The first longitudinal model‐based meta‐analysis of ACR20 is presented, which shows that, with the tested doses/regimens of canakinumab, there was only a low probability that this drug would be better than the most effective current treatments.
Journal ArticleDOI
A Model for Glucose, Insulin, and Beta-Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes
Jakob Ribbing,Jakob Ribbing,Bengt Hamrén,Bengt Hamrén,Maria Svensson,Maria Svensson,Mats O. Karlsson +6 more
TL;DR: A semi‐mechanistic PKPD model incorporating fasting plasma glucose, fasting insulin, insulin sensitivity, and BCM in patients at various disease stages was developed and well described the heterogeneous populations, ranging from nondiabetic, insulin‐resistant subjects to long‐term treated T2DM patients.